CDK4 and neoplasm: Previous studies have demonstrated that miR-506 exerts its tumor-suppressive effects by directly targeting the 3′-UTR of CDK4/6, key regulators of the G1/S transition, thereby inducing G1 phase arrest and inhibiting cancer cell proliferation (72, 107).